Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

Roy S. Herbst, Rafat Ansari, F. Bustin, Patrick J. Flynn, Lowell L. Hart, Gregory A. Otterson, Gordana Vlahovic, Chang-Heok Soh, Paula G. O’Connor, John D. Hainsworth

The Lancet · 2011 · 393 citations · 32 references

DOIFull text

Open access

Concepts

References

32